NCT05944965View on ClinicalTrials.gov

Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 22, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

December 1, 2024

Conditions
OSA
Interventions
DRUG

Atomoxetine 80 mg plus Oxybutynin 5 mg

80mg Atomoxetine and 5mg Oxybutynin administered 30mins prior to bed

DRUG

Atomoxetine 80 MG

80mg Atomoxetine administered 30 mins prior to bed

DRUG

Placebo

Placebo and placebo (sugar pill) administered 30 mins prior to bed

Trial Locations (1)

02115

Brigham and Womens Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT05944965 - Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter